RESUMO
3-O-trans-caffeoyloleanolic acid (COA) is a pentacyclic triterpenoid compound, with significant anti-inflammatory effects. In this study, we report the protective effects of COA on lipopolysaccharide (LPS)-induced acute lung injury (ALI) and explored its mechanism of action. LPS was used to construct in vivo mouse ALI models to observe the effects of COA pretreatment on lung pathology, inflammation, and oxidative stress. In vitro, mouse alveolar macrophages MH-S cells were cultured and stimulated with LPS to investigate the effects of COA pretreatment on inflammation and oxidative stress. Western blotting was used to investigate the expression of iNOS, TLR4, p-p65, p-AKT, and p-PI3K from in vivo and in vitro samples. The results showed that COA significantly improved lung injury, inhibited neutrophil infiltration, prevented macrophage infiltration, inhibited the release of inflammatory factors, reduced oxidative stress, and down-regulated the expression of iNOS, TLR4, p-p65, p-AKT, and p-PI3K in ALI mice caused by LPS. In vitro, COA inhibited the release of inflammatory factors, reduced oxidative stress, and down-regulated the expression of iNOS, TLR4, p-p65, p-AKT, and p-PI3K in MH-S cells stimulated with LPS. Of interest, the protective effects of COA were significantly attenuated in MH-S cells pretreated with the PI3K phosphopeptide activator 740Y-P with no effect on TLR4 expression observed. Taken together, these findings confirm the protective effects of COA on ALI. We further demonstrate that the anti-inflammation and antioxidant effects of COA are mediated through its effects on PI3K/AKT and potentially TLR4.
Assuntos
Lesão Pulmonar Aguda/tratamento farmacológico , Anti-Inflamatórios/química , Ácido Oleanólico/análogos & derivados , Estresse Oxidativo/efeitos dos fármacos , Fosfatidilinositol 3-Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Animais , Anti-Inflamatórios/farmacologia , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Lipopolissacarídeos/metabolismo , Macrófagos/citologia , Masculino , Camundongos Endogâmicos BALB C , Óxido Nítrico Sintase Tipo II/metabolismo , Ácido Oleanólico/química , Ácido Oleanólico/farmacologia , Fosfopeptídeos/metabolismo , Transdução de Sinais , Receptor 4 Toll-Like/metabolismoRESUMO
Gold nanoparticles (AuNPs) have been widely used in many applications. Their usage as drug delivery vehicles has also gained considerable attention due to their chemical and optical properties as well as their good biocompatibility. The present study was conducted to evaluate the efficiency of AuNPs in enhancing the cytotoxic and apoptotic induction activity of lantadene A (LA), separated from Lantana camara leaves, on the breast tumor cell line MCF-7 in vitro. By utilizing plant-mediated synthesis method of nanostructures, LA-loaded AuNPs (LA-AuNPs) were prepared and their formation was confirmed by means of ultraviolet-visible spectroscope, atomic force microscope, scanning electron microscope, and zeta potential. The cytotoxic effect of LA-AuNPs was analyzed using a methylthiazol tetrazolium assay and compared to free AuNPs and LA. The results indicated a significant increase in the reduction of MCF-7 cells viability after incubation with LA-AuNPs. As determined by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, LA-AuNPs induced a greater ratio of DNA-fragmented cells compared to LA-treated and untreated cells. Also, by operating real-time polymerase chain reaction, LA-AuNPs-treated cells displayed an increased upregulation of p53 expression and downregulation of BCL-2 expression in addition to a significant reduction in the level of BCL-2-BAX ratio. No significant effect was shown on the expression of BAX. Collectively, our results indicate that LA-AuNPs showed promising cytotoxicity to MCF-7 cells as a novel nanoscale preparation, likely via induction of apoptotic genes and stimulation of DNA fragmentation.
Assuntos
Antineoplásicos Fitogênicos/toxicidade , Ouro/toxicidade , Mutagênicos/toxicidade , Nanopartículas/toxicidade , Ácido Oleanólico/análogos & derivados , Antineoplásicos Fitogênicos/química , Apoptose/efeitos dos fármacos , Apoptose/genética , Sobrevivência Celular/efeitos dos fármacos , Dano ao DNA , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Ouro/química , Humanos , Lantana , Células MCF-7 , Mutagênicos/química , Nanopartículas/química , Ácido Oleanólico/química , Ácido Oleanólico/toxicidade , Folhas de PlantaRESUMO
Six new triterpenoids, euscaphic acids G-L (1-6), along with nine known triterpene acids, and two known lignans were isolated from the ethanolic extract of the twigs of Euscaphis japonica. This is the first report concerning 1α,3ß-dihydroxy-12-oleanen-28-oic acid isolated from a natural source. The structures of the new compounds were established by spectroscopic analysis. The cytotoxic and anti-NO production activities for the isolates are also evaluated and discussed; compound 1, hederagenin (11), and arjunic acid (12) showed significant cytotoxicity against NCI-H460 cells, HT-29 cells, and CEM cells (IC50 = 1.64 ± 0.87, 2.11 ± 1.54, 1.73 ± 0.64 µM, respectively). Some of the isolated triterpenoids showed marginal inhibitions on NO production induced by LPS.
Assuntos
Antineoplásicos Fitogênicos/farmacologia , Magnoliopsida/química , Ácido Oleanólico/análogos & derivados , Extratos Vegetais/farmacologia , Triterpenos/farmacologia , Animais , Antineoplásicos Fitogênicos/química , Antineoplásicos Fitogênicos/isolamento & purificação , Linhagem Celular Tumoral , Sobrevivência Celular , Humanos , Concentração Inibidora 50 , Lignanas/química , Lignanas/isolamento & purificação , Lignanas/farmacologia , Macrófagos/efeitos dos fármacos , Camundongos , Estrutura Molecular , Óxido Nítrico/metabolismo , Ácido Oleanólico/química , Ácido Oleanólico/isolamento & purificação , Ácido Oleanólico/farmacologia , Extratos Vegetais/química , Extratos Vegetais/isolamento & purificação , Polissacarídeos/efeitos adversos , Triterpenos/química , Triterpenos/isolamento & purificaçãoRESUMO
INTRODUCTION: Non-volatile oleoresins from neotropical Burseraceae are traditionally used for craft, technological and medicinal purposes. The crude resin is usually sold in popular markets of the forest communities. Adding value to this rainforest raw material requires establishing its composition. OBJECTIVE: To analyse the resin composition from different Burseraceae species and establish a minimally reproducible profile by gas chromatography, in order to parameterise its quality control. METHODOLOGY: Crude oleoresin samples of 10 Protium and Trattinnickia species and a commercial blend were subjected to hydrodistillation to remove volatile compounds. The chloroform-soluble residues were methylated, analysed by GC-FID (flame ionisation detection), and individual components were identified by analysing their mass fragmentation pattern in GC-MS and comparison with data from the literature. The blend solubility was assayed in 30 non-chlorinated solvents at three different proportions. RESULTS: The resins consisted exclusively of triterpenes, showing a common predominance of four major compounds in all the samples, corresponding to α-amyrin, ß-amyrin, α-amyrenone and ß-amyrenone. This profile was complemented with minor amounts of the tetracyclic ß-elemolic and α-elemolic acids, maniladiol, brein and other oxidised trace compounds. The better solvents for the resin were those chemically bearing more than four carbon atoms, as n-butyl acetate, 2-ethoxyethanol and isopropanol. The crude resin blend sold contained around 10% of insoluble material that was constituted by up to 70% inorganic residues mixed with humic acid derivatives, as attested by ash analysis and IR spectroscopy, respectively. CONCLUSION: The experimental results, complemented by a general inspection of the literature, demonstrated a systematically reproducible triterpene profile in Protium and Trattinnickia species.
Assuntos
Burseraceae/química , Extratos Vegetais/química , Resinas Vegetais/química , Destilação/métodos , Cromatografia Gasosa-Espectrometria de Massas , Metilação , Estrutura Molecular , Peso Molecular , Ácido Oleanólico/análogos & derivados , Ácido Oleanólico/química , Ácido Oleanólico/isolamento & purificação , Extratos Vegetais/análise , Controle de Qualidade , Reprodutibilidade dos Testes , Resinas Vegetais/análise , Solubilidade , Solventes/química , América do Sul , Triterpenos/análise , Triterpenos/química , Compostos Orgânicos Voláteis/químicaRESUMO
UNLABELLED: Mints (Mentha spp.), aromatic crops grown largely for their essential oils, also are rich sources of nonvolatile antiinflammatory agents. Identification and quantitation of the constituents responsible for their antiinflammatory activity is challenging owing to the lack of suitable chromatographic methodology. In the present research, the simultaneous quantitation of antiinflammatory constituents rosmarinic acid, oleanolic acid, and ursolic acid in mints was attained by using a unique tandem HPLC column system coupled with an electrospray ionization mass detection (MRM mode). The ion mode optimization for rosmarinic acid under negative and triterpenoid acids under positive was achieved by setting 2 time segments in a single run where the polarity mode was switched from negative (0 to 10 min) to positive (10 to 40 min). For the investigated concentration ranges of antiinflammatory agents in mints, good linearities (r² ≥ 0.998) were obtained for each calibration curve. Validation of precision and accuracy for this method showed that intra- and inter-day repeatabilities for all analytes were less than 5.51%, and the recoveries varied from 97.8% to 99.3%. The developed LC/MS/MS assay provides a suitable quality control method for the determination of antiinflammatory constituents in Mentha spp. There is a wide range of diversity in the natural product composition for these acids across the Mentha germplasm collection evaluated. The presence of these antiinflammatory acids in post-distilled mints shows that value-added nutraceutical enriched products can be developed with proper processing and recovery systems in addition to the distillation and capture of the valuable volatile essential oils. PRACTICAL APPLICATION: Results from this research would benefit both commercial farmers growing mint for essential oil and those in the food industry where value-added phytopharmaceutical enriched products can be developed with proper processing, quality control, and recovery systems during mint essential oil distillation.
Assuntos
Anti-Inflamatórios não Esteroides/análise , Cinamatos/análise , Depsídeos/análise , Mentha/química , Ácido Oleanólico/análise , Componentes Aéreos da Planta/química , Extratos Vegetais/química , Triterpenos/análise , Animais , Anti-Inflamatórios não Esteroides/química , Anti-Inflamatórios não Esteroides/economia , Anti-Inflamatórios não Esteroides/farmacologia , Linhagem Celular Transformada , Fenômenos Químicos , Cromatografia Líquida de Alta Pressão , Cinamatos/química , Cinamatos/economia , Cinamatos/farmacologia , Depsídeos/química , Depsídeos/economia , Depsídeos/farmacologia , Destilação , Resíduos Industriais/análise , Resíduos Industriais/economia , Ativação de Macrófagos/efeitos dos fármacos , Camundongos , Óleos Voláteis/economia , Ácido Oleanólico/química , Ácido Oleanólico/economia , Ácido Oleanólico/farmacologia , Reprodutibilidade dos Testes , Especificidade da Espécie , Espectrometria de Massas por Ionização por Electrospray , Espectrometria de Massas em Tandem , Triterpenos/química , Triterpenos/economia , Triterpenos/farmacologia , Ácido Rosmarínico , Ácido UrsólicoRESUMO
Shionogi and GlaxoSmithKline (GSK), as the joint venture company Shionogi-GlaxoSmithKline Pharmaceuticals LLC, are developing S-0139 (SB-737004), an endothelin-A (ETA) antagonist, for the potential treatment of hemorrhagic and ischemic stroke [223386], [252007], [426822], [426830]. By 1999, the compound was in phase II trials in Japan for stroke [348554]; phase II trials were ongoing in March 2002 [446957]. As of May 2000, Shionogi was preparing to develop the drug in the US and Europe [370602]. As of May 2001, a phase I European trial was in preparation [410912]; which was underway by November 2001 [429990]. In July 2001, Shionogi and GSK signed a letter of intent to create a joint venture that was initially to have exclusive rights to develop and commercialize four compounds contributed by Shionogi and one by GSK, including S-0139 14167621. The agreement wasfinalized in October 2001 [426569], [426822]. In August 1999, Lehman Brothers gave S-0139 a 10% probability of reaching the market with an expected launch in 2005. Sales were expected to peak at US $50 million in 2012 [349228].